Clinical Trial Detail

NCT ID NCT01160211
Title A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

Her2-receptor positive breast cancer

Therapies

Lapatinib + Trastuzumab

Letrozole

Anastrozole

Lapatinib

Trastuzumab

Exemestane

Age Groups: adult senior

Additional content available in CKB BOOST